Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial-Reference-Cited by-同舟云学术

Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial

Published:2016-03 Issue:10024 Volume:387 Page:1178-1186
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Greenberg Barry,Butler Javed,Felker G Michael,Ponikowski Piotr,Voors Adriaan A,Desai Akshay S,Barnard Denise,Bouchard Alain,Jaski Brian,Lyon Alexander R,Pogoda Janice M,Rudy Jeffrey J,Zsebo Krisztina M

Publisher

Elsevier BV

Subject

General Medicine

Reference25 articles.

1. Morbidity and mortality: 2012 chart book on cardiovascular, lung, and blood diseases,2012

2. Relation between myocardial function and expression of sarcoplasmic reticulum Ca2+-ATPase in failing and nonfailing human myocardium;Hasenfuss;Circ Res,1994

3. Calcium cycling in congestive heart failure;Hasenfuss;J Mol Cell Cardiol,2002

4. Altered sarcoplasmic reticulum calcium cycling—targets for heart failure therapy;Kho;Nat Rev Cardiol,2012

5. Sarcoplasmic reticulum Ca-ATPase and heart failure 20 years later;Eisner;Circ Res,2013

Cited by 381 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Type I collagen-targeted liposome delivery of Serca2a modulates myocardium calcium homeostasis and reduces cardiac fibrosis induced by myocardial infarction;Materials Today Bio;2024-10

2. Pathological mutations in the phospholamban cytoplasmic region affect its topology and dynamics modulating the extent of SERCA inhibition;Biochimica et Biophysica Acta (BBA) - Biomembranes;2024-10

3. Gene therapy for polygenic or complex diseases;Biomarker Research;2024-09-04

4. Reversal of contractile defects by mediating calcium homeostasis in human mini-heart models of heart failure with preserved ejection fraction (HFpEF) leads to first-in-human gene therapy clinical trial;2024-08-28

5. Current developments of gene therapy in human diseases;MedComm;2024-08-16